



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> C12N 15/62, 15/70, C12P 21/00 C12P 21/02, C07K 7/20, 15/06 C07K 15/12, A61K 39/385, 37/38 // (C12N 15/62, C12R 1/19) (C12N 15/70, C12R 1/19)	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/02799</b>  <b>(43) International Publication Date:</b> 7 March 1991 (07.03.91)
<b>(21) International Application Number:</b> PCT/AU90/00373 <b>(22) International Filing Date:</b> 24 August 1990 (24.08.90)  <b>(30) Priority data:</b> PJ 5979 25 August 1989 (25.08.89) AU  <b>(71) Applicant (for all designated States except US):</b> BIOTECH- NOLOGY AUSTRALIA PTY LTD [AU/AU]; 28 Bar- coo Street, Roseville, NSW 2069 (AU).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> RUSSELL-JONES, Gregory, John [AU/AU]; 23 Greenfield Avenue, Middle Cove, NSW 2068 (AU). STEWART, Andrew, George [GB/AU]; 26 Bobbin Head Road, Pymble, NSW 2073 (AU). TSONIS, Con, George [AU/AU]; 8 Beaumont Avenue, Denistone, NSW 2114 (AU).	<b>(74) Agent:</b> GRIFFITH HACK & CO; 71 York Street, Sydney, NSW 2001 (AU).  <b>(81) Designated States:</b> AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent)*, DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (Eu- ropean patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> FUSION PROTEINS  <b>(57) Abstract</b>  This invention relates to the preparation of novel fusion proteins which comprise an analogue of LHRH and TraTp or an analogue of TraTp. The fusion proteins of the invention are useful as components of vaccines for the inhibition or control of reproductive functions in vertebrate hosts. The invention also relates to polynucleotide molecules encoding the fusion proteins, to transformant hosts expressing the fusion proteins and to methods of inhibiting or controlling reproductive function in vertebrate hosts using the fusion proteins or vaccines of the invention.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

- 1 -

FUSION PROTEINSTechnical Field

This invention relates to fusion proteins useful as components of vaccines for the immunological castration or inhibition of reproductive function of vertebrate hosts in general and domesticated animals in particular.

Background Art

The most popular method of preventing reproductive activity in domestic animals, including dogs, horses, sheep, cattle, goats and cats, is surgical ovariectomy or castration.

This method suffers from the problem that it is irreversible and is, technically, a relatively difficult procedure, therefore requiring the skills of trained veterinarians.

One of the alternative methods to surgery is the administration of progestagen steroids which can be used as long term oestrus suppressants (Harris and Wotchuk Am. J. Vet. Res. 24: 1003-1006, 1963) in dogs, but are unfortunately associated with the induction of uterine disorders including pyometritis, endometritis and increased incidence of benign mammary tumours following long term treatment. Their use has therefore tended to become confined to short term suppression of oestrus or postponement of oestrus.

In economically important farm animals there is no commonly used long term contraceptive which has been found to be suitable for routine use in the field.

There is therefore a need for a well-tolerated non-steroidal method of contraception in domestic animals which is applicable to both male and female domestic animals.

One such method would be to immunise against the hormones which control the development and activity of the reproductive organs.

The two gonadotrophic hormones which regulate gonadal steroidogenesis and gametogenesis, and are responsible for

- 2 -

reproductive cyclicity are luteinizing hormone (LH) and follicle stimulating hormone (FSH).

5 Luteinizing hormone releasing hormone (LHRH, also known as GnRH) controls the synthesis and release of LH and FSH from the anterior pituitary gland. Mammalian LHRH is a decapeptide comprised of naturally occurring amino acids in the following sequence:

(pyro) - Glu - His - Trp - Ser - Tyr - Gly - Leu - Arg - Pro - Gly - NH<sub>2</sub>

10 The N and C terminal glutamic acid and glycine residues are modified after translation to pyroglutamic acid and glycnamide respectively.

Vaccines which result in the production of antibodies against LHRH by a host will suppress that host's endogenous LH and FSH production and release. This suppression can result in reduction of steroidogenesis and a failure of reproductive cyclicity and fertility in the treated animal.

The resultant physiological effects are

(a) in the female:-

- 20 (i) a cessation of LH pulsatility,  
(ii) a failure of ovulation leading to infertility  
(iii) a cessation of oestrus cycles due to the lack of oestrogens,  
(iv) regression of the reproductive tract  
25 (v) abortion due to regression of the corpus luteum

(b) in the male:-

A suppression of production of testosterone from the Leydig cells in the testes resulting in lowered peripheral blood serum levels of circulating androgens, causes:

- 30 (i) reduced libido,  
(ii) regression of the accessory sex glands, and  
(iii) diminution in the testicular volume and reduction/cessation of spermatogenesis.

35 Antibodies against LHRH can be produced in a number of species by chemically conjugating LHRH to a suitable

- 3 -

carrier and administering it in the presence of an appropriate adjuvant (Carrelli C. et al, 1982, Proc. Natl. Acad. Sci USA 79 5392-5395). Chemical conjugation is however, difficult to control and often results in a heterogeneous and ill-defined product. Moreover, an oil-based adjuvant is usually required for effective immunisation and this often leads to the formation of unacceptable side effects such as inflammation and granulomatous tissue lesions.

10           It is desirable to provide a means for producing good titres of antibodies against LHRH without the need to use strong adjuvants.

          The TraT protein (TraTp) is coded by the TraT gene. TraTp is an outer membrane lipo-protein produced by certain strains of E. coli and is responsible for the resistance of these strains to killing by serum. When injected intramuscularly into mice, without adjuvant, TraTp elicits an antibody response which is comparable to that obtained when it is injected with incomplete Freund's adjuvant.

15           Furthermore, chemical coupling of an immunogen to TraTp followed by administration of the complex in saline to an animal results in the production of high levels of anti-immunogen antibodies. TraTp, therefore, can be used as a self-adjuvanting carrier of immunogens. This use of TraTp has been described previously in International Patent Application No. PCT/AU87/00107 (published as WO 87/06590), wherein both chemical and genetic linkage of TraTp to immunogen molecules was described. The specific fusions made and described in that specification relate to large proteins. On the other hand, LHRH is a short peptide which makes it inherently difficult to use as an immunogen without a suitable carrier. Furthermore, as there is little variation in the peptide between species, it is seen as a self-antigen by the immune system and is consequently recalcitrant to the stimulation of an immune response.

20           Fusion proteins comprising LHRH sequences and LTB (the

25

30

35

- 4 -

B subunit of the heat labile toxin produced by certain strains of E. coli) have been described (International Patent Application No. PCT/AU86/00135 published as WO86/06635). These constructs were prepared for the purpose of orally presenting LHRH to the immune system of a host, using the ability of LTB to bind to mucosal epithelium. They are not self-adjuvanting and although inhibition of reproductive function was demonstrated, the resulting inhibition was not a strong inhibition.

PCT/EP89/01013 (published as WO 90/02187) describes the production of fusion proteins including a peptide which alone is not substantially antigenic such as LHRH using a "carrier" which is a highly antigenic, hydrophilic protein such as hepatitis B surface antigen. TraTp is a membrane lipoprotein and is not a highly hydrophilic protein. Further the fusions taught in PCT/EP89/01013 do not appear to be self-adjuvanting.

#### Abbreviations

LHRH:	Luteinizing Hormone Releasing Hormone
20 LH:	Luteinizing Hormone
GnRH:	Gonadotrophin Releasing Hormone (is another name for LHRH)
FSH:	Follicle Stimulating Hormone
LTB:	The B subunit of the heat-labile toxin produced by certain strains of <u>E. coli</u>
25 QC:	Quality Control
QA:	Quality Assurance
EDTA:	Ethylene diaminetetra-acetic acid
SDS:	Sodium Dodecyl Sulphate
30 SDS-PAGE:	Sodium Dodecyl Sulphate Polyacrylamide gel electrophoresis
LPS:	Lipopolysaccharide
EDAC:	1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide HCl
35 ABTS:	2,2 <sup>1</sup> -Azinobis(3-ethylbenzthiazoline sulphonic acid)
PEG:	Polyethylene glycol

- 5 -

	BSA:	Bovine Serum Albumin
	IF:	Insoluble form of the fusion protein
	SF:	Soluble form of the fusion protein
	PHA:	Phytohaemagglutinin
5	MBS:	m-maleimido benzoic acid n-hydroxysuccinimide ester
	A <sub>280</sub> :	Absorbance, at a setting of 280nm on the spectrophotometer
	ISA-20:	Montanide adjuvant, SEPPIC
10	ISA-25:	Montanide adjuvant, SEPPIC
	sem:	Standard error of the Mean
	sd;	Standard deviation
	PBS:	Phosphate Buffered Saline, pH 7.2-7.4
	w/w:	Weight for weight
15	v/w:	Volume for weight
	DNA:	Deoxyribonucleic acid
	NSB:	Non-specific binding

#### Definitions

20 TraTp refers to the protein product of the TraT gene.  
TraTp-LHRH denotes a fusion protein formed as the expression product of a TraT and LHRH gene fusion.

TraTp-LHRH protein fusions are denoted as 730p, 731p etc., according to the plasmid which expressed them.

Plasmids are denoted as pBTA 730, etc.

25 E. coli/plasmid combinations are denoted as BTA 1664, etc.

TraTp analogues according to the present invention are molecules related to the TraTp sequence where alterations such as insertions, deletions or substitutions occur due to the strategy used for the fusion of LHRH analogue sequences to the TraTp sequences.

35 LHRH analogues according to the present invention are molecules related to the LHRH sequence where amino acid differences occur which take into account either variations in the above identified sequence which occur between species, variations in post-translational modifications to particular residues which occur because of particular fusion

- 6 -

strategies or variations in amino acid sequence which occur because of particular fusion strategies.

Description of the Invention

5 In the present invention, particular insertion sites in TraTp have been identified which lead to the production of novel fusion proteins of TraTp or an analogue thereof and analogues of LHRH, capable of eliciting strong immune responses to LHRH. The present inventors have shown that not all fusions of LHRH analogues and TraTp or TraTp  
10 analogues are suitable for producing good titres of antibodies against LHRH. Further, between species variations were seen in the effect of different multimers of an LHRH analogue in a particular location in TraTp.

The present invention demonstrates that fusion of  
15 LHRH analogue coding sequences to TraTp or TraTp analogue coding sequences can be used to effectively provide vaccines useful in the inhibition or control of reproductive function in vertebrate hosts and particularly in domesticated animals.

According to the present invention recombinant DNA  
20 technology can be used to produce novel fusion proteins of TraTp or TraTp analogues and LHRH analogues which, when administered in saline or an adjuvant such as saponin lead to the production of antibodies which recognise LHRH (referred to hereafter as LHRH antibodies) which, in turn,  
25 inhibit reproductive functions in animals.

Work with immunogenic fusions exemplified herein shows that insertion of tandem repeats of LHRH analogues gives a more immunogenic fusion than the insertion of a single insert.

30 Advantages associated with making the fusion proteins in E. coli compared with chemical conjugation of TraTp and LHRH include:

- a) the production process is simpler than that for chemical conjugation;
- 35 b) it is easier to define the nature of a fusion protein product than that of a chemical conjugate, thus giving product quality control (QC) and production quality assurance (QA) advantages; and



- 7 -

c) fusions provide greater specificity and flexibility than chemical conjugation because the exact position of insertion of the LHRH analogue into TraTp or a TraTp analogue can be selected and the number of repeating epitopes can be chosen to give the optimum immunological response.

The invention provides novel fusion proteins. These fusion proteins may comprise a single copy of an analogue of the LHRH decapeptide inserted into or fused to TraTp or an analogue thereof or may comprise multiple copies of LHRH analogue which may be inserted at multiple locations within TraTp or the TraTp analogue. Particular cloning strategies may necessitate the inclusion of nucleotides coding for sequences which are not native to LHRH, the analogue or TraTp, or may lead to the deletion of bases from coding sequences.

Preferably, the fusion comprises the LHRH analogue Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly.

Preferably, the at least one LHRH analogue is inserted between amino acids 80 and 81, 200 and 201 or 235 and 236 of the TraTp sequence, or in a combination of these sites where amino acid 1 is the Met 1 of the TraTp signal sequence.

The novel fusion proteins of the invention can be utilised to provide vaccines suitable for administration to domestic animals to inhibit or modify reproductive function in those animals.

The present invention also provides a polynucleotide molecule which encodes a fusion protein of the invention.

Preferred polynucleotide molecules are recombinant DNA molecules. More preferably, the recombinant DNA molecules comprise plasmid vectors. A preferred vector is pBTA 812. It will be recognised that vectors other than plasmid vectors could be used. Other vectors include other expression systems including viral, cosmid and phasmid vectors.

- 8 -

The invention further provides a transformant host carrying a polynucleotide molecule of the invention. Typically, the host is a bacterial host such as E. coli. A preferred host is E. coli strain N 4830 which is used in conjunction with a polynucleotide molecule of the invention wherein the fusion gene is under control of the  $P_L$  promoter. Other hosts which could be used include yeasts, fungi, other bacterial hosts and other eukaryotic hosts including insect and mammalian cell lines.

10 The vaccines of the invention comprise at least one fusion protein of the invention together with a carrier, diluent, excipient and/or adjuvant suitable for human or veterinary use.

15 The amount of fusion protein that may be combined with carrier to produce a single dosage form will vary depending upon the condition being induced, the host to be treated and the particular mode of administration.

20 It will be understood, also, that the specific dose level for any particular host will depend upon a variety of factors including the activity of the specific fusion protein, the age, body weight, general health, sex and diet of the host, time of administration, route of administration, rate of excretion, and drug combination.

25 The vaccines of the present invention may be administered orally, parenterally, rectally or vaginally in dosage unit formulations containing conventional, non-toxic, pharmaceutically acceptable carriers, diluents, adjuvants and/or excipients as desired.

30 Injectable preparations, for example, sterile injectable aqueous or oleagenous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as  
35 a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's

solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Suitable adjuvants for the vaccination of animals or humans include but are not limited to saponin, oil emulsions such as Montanide ISA-20 or Montanide ISA-25, Marcol 52: Montanide 888 (Marcol is a Trademark of Esso. Montanide, Montanide ISA-20 and Montanide ISA-25 are Trademarks of SEPPIC, Paris), squalane or squalene, Adjuvant 65 (containing peanut oil, mannide monooleate and aluminium monosterate), mineral gels such as aluminium hydroxide, aluminium phosphate, calcium phosphate and alum, surfactants such as hexadecylamine, octadecylamine, lysolecithin, dimethyldioctadecylammonium bromide, N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl) propanediamine, methoxyhexadecylglycerol and pluronic polyols, polyanions such as pyran, dextran sulfate, DEAE-dextran, polyacrylic acid and carbopol, peptides and amino acids such as muramyl dipeptide, dimethylglycine, tuftsin and trehalose dimycolate. The fusion proteins of the present invention can also be administered following incorporation into liposomes or other micro-carriers, or after conjugation to polysaccharides, proteins or polymers or in combination with Quil-A to form "Iscoms" (Immunostimulating complexes) (Morein *et al.*, Nature 308, 457-460 [1984]).

Routes of administration, dosages to be administered as well as frequency of injections are all factors which can be optimized using ordinary skill in the art. Typically, the initial vaccination is followed some weeks later by one or more "booster" vaccinations, the net effect of which is the production of high titres of antibodies against the immunogen.

Suppositories for rectal or vaginal administration of the fusion proteins of the invention can be prepared by

- 10 -

mixing the fusion protein with a suitable nonirritating excipient such as cocoa butter, theobroma oil, glycerinated gelatin or polyethylene glycols which are solid at ordinary temperatures but liquid at rectal or vaginal temperature or  
5 by contact with fluids present in the appropriate cavity and will therefore melt in the rectum or vagina and release the fusion protein.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In  
10 such solid dosage forms, fusion proteins may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the  
15 case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include nanoparticles, microcapsules, in pharmaceutically  
20 acceptable emulsions, syrups, solutions, suspensions, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents and sweetening, flavouring, and perfuming  
25 agents including sugars such as sucrose, sorbitol, fructose etc, glycols such as polyethylene glycol, propylene glycol etc, oils such as sesame oil, olive oil, soybean oil etc, antiseptics such as alkylparahydroxybenzoate etc, and flavours such as strawberry flavour, peppermint etc.

30 The invention further provides a method of controlling reproductive function in a vertebrate host which is preferably a domestic animal which method comprises administering a fusion protein or a vaccine of the invention to the host to vaccinate the host.

35 The invention also provides a method for inhibiting reproductive function in a vertebrate host which is preferably a domestic animal which method comprises

- 11 -

administering a fusion protein or vaccine according to the invention to the host, to vaccinate the host.

The fusion proteins of this invention, therefore have application in the control of fertility and reproductive cyclicity of vertebrates generally, but in particular the control of mammalian reproductive activity in pet animals such as the dog and cat and in animals used for commercial purposes such as cattle, sheep, goats, pigs, horses, etc.

Fusion proteins of the invention are typically synthesised in E. coli following the expression of a chimeric gene coding for TraTp or a TraTp analogue and an LHRH analogue.

There are several possible strategies by which such chimeric genes may be made. These include but are not limited to:

1. Random insertion: Using appropriate gene construction techniques, LHRH analogues may be positioned anywhere within the TraT protein or an analogue thereof. The product can be tested for anti-LHRH immunogenicity and the best construct selected as the basis of a vaccine. There are a number of possible methods.
  - a) DNA coding for TraTp or an analogue thereof may be subjected to random cleavage using DNase I [Lin et al Anal. Biochem. 197, 114-119 (1985)], a DNA fragment coding for an LHRH analogue is inserted and the resulting plasmid cloned into E. coli. By placing the TraT gene under the control of a suitable promoter, induction will result in a proportion of the recombinant clones expressing fusions which can be selected by colony immunoassay with LHRH antibodies for further characterisation.
  - b) by insertion of LHRH analogue encoding DNA at convenient restriction sites in the TraT gene. The DNA insert should be tailored to be compatible with the various cohesive termini produced by different

- 12 -

restriction endonucleases and should retain the translational reading frame.

2. Directed insertion: Insertion of an LHRH analogue within the TraTp or TraTp analogue sequence such that it is exposed on the surface of the TraTp or TraTp analogue may cause minimal disruption of TraTp or the LHRH analogue and result in optimal presentation of the TraTp-LHRH conjugations in which LHRH is preferably located on the outer surface of the molecule. An alternative approach would be to replace part of the TraTp with an LHRH analogue. This directed insertion is performed by construction of suitable restriction enzyme sites at specific locations in the gene sequence.
3. An LHRH analogue may be inserted as a monomer at one site in TraTp or a TraTp analogue; as a monomer at more than one site or as multiple copies at one or more sites.
4. Analogues of LHRH, containing amino acid substitutions, insertions or deletions at one or more sites, may be used in any of the above means. It must be noted that the amino-terminal pyroGlu of LHRH cannot be formed when the amino acid sequence encoded by an LHRH gene is within a fusion protein. Therefore expression of the gene results in a Glu-1 analogue of LHRH within the TraTp protein. Similarly, the carboxy-terminus of the native molecule is a glycynamide residue as a result of post-translational processing. When the amino acid sequence coding for LHRH is positioned in a fusion such that this is an internal residue post-translational processing will not occur and therefore a Gly-10 analogue of LHRH results.
- Other useful analogues include but are not limited to;  
(a) naturally occurring variants of LHRH such as:-  
chicken I: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Gln-Pro-Gly-NH<sub>2</sub>;

chicken II:

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH<sub>2</sub>;

Salmon: pyroGlu-His-Trp-Ser-Tyr-Gly-Trp-Leu-Pro-Gly-NH<sub>2</sub>;

(b) Glu-1, His-1, Pro-1 and Lys-6 analogues.

5

Brief Description of the Drawings

- Figure 1: A. Map of the plasmid pBTA 812 that expresses the TraT gene. B. Sequence of the P<sub>L</sub> promoter and the 5' untranslated region of the TraT gene.
- 10 Figure 2: Coding sequence of TraT and derived peptide sequence of TraTp. Numbers below each line refer to the amino acids. Restriction sites used for the insertion of the LHRH analogue coding sequence are shown.
- 15 Figure 3: DNA and amino acid sequence of TraTp-LHRH fusion proteins. Only the LHRH analogue and the neighbouring TraTp sequence is shown for each construct. Numbers refer to the amino acids in TraTp.
- 20 Figure 4: (a) Sequence of DNA fragments coding for LHRH analogue  
(b) Sequence of linker DNA  
(c) Sequence of LHRH analogue DNA used in the construction of pBTA 870  
25 (d) Sequence of LHRH analogue dimer DNA used in the construction of pBTA 862.
- Figure 5: Sequence of multimeric inserts of LHRH analogue in TraTp. The numbers denote amino acids in TraTp, as in Figure 2.
- 30 Figure 6: Proliferative responses of T-cells from dogs immunised with 732p in various formulations. Data are presented as the mean  $\pm$  sd. Stimulation index, was calculated by dividing the c.p.m. in the presence of antigen, by c.p.m. in the absence of antigen.
- 35 Figure 7: The mean ( $\pm$  sem) LHRH serum antibody response from dogs immunised on Days 0, 28 & 56, with 732p

- 14 -

in various formulations. Blood samples (5-8ml) were collected from the cephalic or jugular veins on Days 0, 28, 42, 56 & 70 and the sera were (at dilution of 1:2000 final) analyzed for their ability to bind  $^{125}\text{I}$ -LHRH in an LHRH tracer binding assay (described in Example 3B).

Figure 8: The mean ( $\pm$  sem) LHRH serum antibody response from dogs immunised on Days 0, 28 & 56, with 732p and Day 121 with TraTp-LHRH fusion protein, 862p containing four inserts of LHRH analogue arranged in tandem. Each dog received 500 $\mu\text{g}$  of 862p in 0.05% saponin and 0.1% SDS. These dogs were bled on Days 121 (prior to booster #3), 134, 141, 155, 162, 164 and 167 and the sera were analyzed for their ability to bind  $^{125}\text{I}$ -LHRH in an LHRH tracer binding assay (described in Example 3B).

Figure 9: The mean ( $\pm$  sem) LHRH serum antibody response was determined on Days 28 and 42, from (a) dogs and, (b) mice, immunised on Days 0 & 28 with TraTp-LHRH analogue fusion proteins, 733p, 870p, 862p, 859p. Sera (at dilution of 1:2000 final) were analyzed for their ability to bind  $^{125}\text{I}$ -LHRH in an LHRH tracer binding assay (described in Example 3B).

Figure 10: Serum testosterone concentrations (ng/ml; described in Example 3C) and, LHRH serum antibody binding in dog #060/10. Blood was taken on Days 0, 28, 42, 56, 70, 84 (immunised, with 732p; 1000 $\mu\text{g}$ ) and 121 (boosting with 862p; 500 $\mu\text{g}$ ), 134, 141, 148, 155, 162, 169 and 176. Days are with respect to the primary immunisation with 732p (at Day 0). Sera (at dilution of 1:2000 final) were analyzed for their ability to bind  $^{125}\text{I}$ -LHRH in an LHRH tracer binding assay (described in Example 3B).

Figure 11: Proliferative response of T-cells from dogs immunised with various TraTp-LHRH analogue fusion



- 15 -

proteins in a saponin/SDS adjuvant. Data are presented as the mean  $\pm$  sd. Stimulation index, was calculated by dividing the c.p.m. in the presence of antigen, by c.p.m, in the absence of antigen.

5

#### Best Mode of Carrying Out the Invention

The recombinant DNA molecules and transformant hosts of the invention are prepared using standard manipulations of molecular biology, such as digestion, ligation etc.

Fusion proteins of the invention are obtained by culturing the transformant hosts of the invention under standard conditions as appropriate to the particular host and separating the fusion protein from the culture by standard techniques. The fusion protein may be used in impure form or may be purified by standard techniques as appropriate to the fusion protein being produced.

The vaccines of the invention are prepared by mixing, preferably homogeneously mixing, fusion protein with a carrier, diluent, excipient and/or adjuvant acceptable for human or veterinary use using standard methods of pharmaceutical preparation.

The amount of fusion protein required to produce a single dosage form will vary depending upon the condition to be induced, host to be treated and the particular mode of administration. The specific dose level for any particular individual will depend upon a variety of factors including the activity of the fusion protein employed, the age, body weight, general health, sex, and diet of the individual, time of administration, route of administration, rate of excretion and drug combination.

The vaccine may be administered orally, parenterally, rectally or vaginally in unit dosage formulations containing conventional, non-toxic, carriers, diluents, excipients and/or adjuvants acceptable for human or veterinary use as desired.

5 PLASMIDS WHICH EXPRESS VARIOUS TraT-LHRH ANALOGUE  
FUSION PROTEINS.

20       The basic TraT expression vector pBTA 812 is  
illustrated in Figure 1. It is derived from plasmid pBR322  
[Bolivar F. et al (1977) Gene 2 95-113] and carries an  
ampicillin resistance gene which permits selection of  
25       plasmid bearing E. coli. (Alternative selectable genes  
could be incorporated such as those coding for other  
antibiotic resistance.) It also carries the leftward  
promoter ( $P_L$ ) of lambda which promotes the transcription  
of the TraT gene [Ogata R.T. et al. (1982) J. Bacteriol. 151  
819-827]. Plasmid BTA 812 is similar to pBTA 439 which was  
30       described in PCT/AU87/00107 (published as WO87/06590) and  
was deposited with the American Type Culture Collection as  
ATCC 67331. pBTA 812 can be made as follows.  $pP_L$ -lambda  
(plasmid and sequence provided by Pharmacia LKB, Uppsala,  
Sweden) is digested with restriction endonucleases SmaI and  
35       EcoRI according to the manufacturers instructions and the  
linear vector religated in the presence of DNA polymerase I  
(Klenow fragment) and deoxynucleotide triphosphates.

- 17 -

(Methodology is as described by T. Maniatis, E. F. Fritsch and J. Sambrook in "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press, 1982). Each ligation step is followed by transformation of the product into a suitable *E. coli* host strain (e.g. C600 $\lambda$  which carries the repressor of the P<sub>L</sub> promoter). The new plasmid now lacks EcoRI, SmaI and one of the BamHI sites. This plasmid can then be cut with HpaI and treated with exonuclease such as Bal31 (Promega) to remove DNA coding for the N gene as well as most of the 5' untranslated N gene DNA, followed by phenol extraction and ethanol precipitation of the DNA. This is then cut with XmnI and DNA of approximately 670 base pairs isolated by electrophoresis on low gelling temperature agarose gels. pBTA439 is cut with SmaI and SacI then religated in the presence of Klenow fragment and deoxynucleotide triphosphates (this removes these sites) followed by cutting with BamHI and BglII and religation (to remove BamHI, SalI, PstI and BglII sites). The resulting plasmid is cut with EcoRI and XmnI and a 3054 base pair fragment isolated by electrophoresis on agarose gels and ligated to the 670 base pair fragment described above in the presence of Klenow fragment and deoxynucleotide triphosphates. Selection by growth on ampicillin ensures the correct orientation of the fragments due to the reconstitution of the  $\beta$ -lactamase gene. The EcoRI site is reconstituted when a G in the top strand of the approximately 670 base pair fragment is next to the AATTC of the 3054 base pair fragment. Recombinant plasmids are screened for the presence of an EcoRI site and the DNA of the positive clones is sequenced in the region of the EcoRI site. The sequence of the P<sub>L</sub> promoter and that corresponding to the 5' untranslated mRNA of pBTA812 is shown in Figure 1.

The P<sub>L</sub> promoter and the expression of TraTp is controlled by the temperature sensitive repressor cI857 which is present in modified *E. coli* strains such as N4830 [see M. Joyce and NDF Grindley (1983) Proc. Natl. Acad. Sci. USA 80 1830-1834].

- 18 -

The full coding sequence of TraTp is shown in Figure 2 (Ogata *op. cit.*). This includes the signal sequence which may be cleaved in *E. coli* between amino acids 20 and 21 to leave an N-terminal cysteine which carries a fatty acid modification [Perumal, N.B. and Minkley E.G. (1984) J. Biol. Chem. 259 5359-5360].

Restriction sites within the TraT gene which have been used as sites of insertion of the LHRH analogue DNA are indicated.

Examples of 8 plasmid constructs which express TraTp-LHRH analogue fusions are illustrated in Figure 3. The unique insertion positions were distributed over the whole of the TraTp molecule.

Plasmid construction; pBTA 812 was prepared by extraction from a suitable *E. coli* K12 host strain (e.g. C600λ) and purification on caesium chloride density gradients.

pBTA 731 was constructed by cutting pBTA 812 with restriction endonuclease HpaI according to manufacturer's instructions and purifying the linear DNA, for example on low gelling temperature agarose (Maniatis *op. cit.*).

DNA coding for LHRH analogue as shown in Figure 4(a) was synthesized by a method based on that described by Beaucage S.L. and Caruthers (1981) Tetrahedron Lett. 22 1859-1862, ligated to the linearised pBTA 812 and transformed into a suitable strain of *E. coli* K12. Plasmid containing cells are selected by plating onto media containing ampicillin. Colonies with plasmids which have the LHRH analogue insert were identified either by colony hybridisation using [<sup>32</sup>P]-labelled LHRH DNA as a probe (Maniatis *op. cit.*) or by picking a number of colonies, extracting the plasmid and determining the presence of a SmaI restriction site which is unique to the LHRH DNA. The correct sequence and orientation of the LHRH analogue DNA and neighbouring TraT DNA was confirmed by dideoxy nucleotide sequencing.

pBTA 730, 733 and 734 were constructed by digesting pBTA 812 with limiting amounts of restriction endonuclease

- 19 -

SspI, ScaI and RsaI respectively such that not all of the sites for those enzymes in the plasmid were cut. Only the plasmid which was cut once with each enzyme was removed from the low gelling temperature agarose gel following electrophoresis. DNA coding for LHRH analogue as shown in Figure 4(a) was ligated into this DNA and E. coli carrying the appropriate new recombinant plasmids were identified as described above. Restriction mapping and DNA sequencing was used to show that the correct restriction site contained LHRH analogue DNA in the correct orientation.

pBTA 732, 735, 737 and 740: these required the construction of intermediates which contain a short linker fragment of DNA inserted at the chosen site. The linker (Figure 4b) provides a unique new SmaI site located between codons such that the DNA coding for LHRH analogue can be inserted in frame for expression of TraTp-LHRH analogue full length fusion proteins.

pBTA 812 was cut to completion with either restriction endonuclease EcoRV, StuI or BalI or partially with HaeIII and linear DNA which has been cut once with each of these enzymes isolated by agarose gel electrophoresis. Linker DNA (Figure 4(b)) was ligated into each of these DNAs and inserted into E. coli. Recombinants were screened by colony hybridisation (using radioactively labelled linker as a probe or by restriction analysis of the DNA from a number of colonies). The linker had been designed such that the SmaI site will be situated between codons depending on the orientation of the linker. The orientation of the linker was determined either by sequencing the DNA in that region or by the presence of a new restriction site when this was created or by inserting the LHRH analogue gene in the SmaI site and assaying the recombinants for the expression of a TraTp-LHRH analogue fusion protein.

The DNA coding for an LHRH analogue (Figure 4) was inserted into the SmaI site of the constructs containing the linkers as described for pBTA 730 above. On determining the nucleotide sequence of the final constructs pBTA 732 was

- 20 -

found to have lost three bases at the 3' junction of the LHRH analogue/linker/TraT DNA.

pBTA 609 is a TraTp-LHRH analogue fusion in which the LHRH analogue has been inserted between amino acids 31 and 32. The codons were converted to a PvuII site by in vitro mutagenesis (the new codons represent Gln and Leu) and the DNA coding for LHRH analogue was inserted into this site. This position was chosen because the protein sequence is particularly hydrophilic in this region. An inserted peptide in this position may be exposed on the surface of the TraTp molecule and may therefore be more antigenic.

pBTA 736 (host vector combination BTA 1669) contains LHRH analogue inserted at two different sites in TraT and is a composite of pBTA 731 and pBTA 732.

Plasmids were also constructed which contained multiple insertions of LHRH analogue at single positions. The construct with two LHRH analogue molecules (pBTA 870) was made by inserting the DNA coding for LHRH analogue as shown in Figure 4(c) into the SmaI site of the LHRH analogue in pBTA 733 and, after transformation, identifying colonies with two LHRH analogue inserts as described above. The original SmaI site was not reconstituted but the new LHRH analogue insert carried a SmaI site in the equivalent position in the second LHRH analogue gene (Figure 5; pBTA 870).

A further construct with four LHRH analogue repeats (pBTA 862) was made by inserting DNA coding for a dimer of LHRH analogue (Figure 4(d)) into the SmaI site of pBTA 870. Again, the original SmaI site was lost and a new SmaI site created near the end of the LHRH analogue DNA. Constructs with six and eight repeats of LHRH analogue were made by successive additions of the LHRH analogue dimer DNA to pBTA 862. The DNA sequence of some of the LHRH analogue genes was varied (making use of codon degeneracy) to avoid plasmid instability which might occur when using multiple identical tandem repeats of DNA.

- 21 -

Figure 5 illustrates plasmids pBTA 870, pBTA 862, pBTA 859 which carry two, four and eight LHRH analogue insertions respectively between amino acids 200 and 201 of TraTp. It can be seen that plasmids similar to pBTA 870, pBTA 862 and pBTA 859 containing multiples of LHRH analogue DNA could be constructed using as starting plasmids pBTA 732 and pBTA 740.

All the above plasmids were inserted into E. coli strains containing the temperature sensitive repressor cI857 [M. Joyce, N.D.F. Grindley, op. cit.] available from Pharmacia LKB, Uppsala, Sweden. Other strains carrying the CI857 repressor might be used instead of N4830. Expression of the TraT-LHRH analogue genes is induced by raising the temperature of the plasmid-bearing E. coli culture from 28°C to between 37°C and 42°C. Each of the constructs produced a TraTp-LHRH analogue protein of the expected sizes. The production levels of each varied with the position of LHRH analogue insertion: most were produced at a higher level than TraTp alone. Following cell breakage, the fusion proteins were extracted and purified for injection into animals as in Example 2.

#### EXAMPLE 2:

##### PURIFICATION OF TraTp-LHRH ANALOGUE FUSION PROTEINS

For the initial screening experiment described in Example 4, a simple fractionation procedure was used to separate the fusion proteins from the bulk of E. coli proteins. The E. coli strains containing the TraTp-LHRH analogue gene fusion plasmids were grown in shake flasks at 30°C and induced at 41°C for 3 hours. Bacteria were harvested by centrifugation (17,000g. for 20 min) and the cells lysed in 0.1M Tris-HCl pH7.5, 10mM EDTA using a French Press. Lysed cells were then separated from inclusion bodies by layering onto 25% glycerol and centrifuging for 15 min at 10,000 x g. Inclusion bodies (pellet) were suspended by sonication into 0.1 M Tris-HCl pH 7.5, 50mM EDTA containing 5% TRITON-X-100. The sonicated material was centrifuged for 20 min at 12,000 x g to give an insoluble

- 22 -

form (IF). A soluble form (SF) was obtained by resuspending the pellet in 0.1 M Tris pH 7.5, 10 mM EDTA and 2% SDS. This material was then precipitated with ethanol to 50% and resuspended in saline (SF) prior to injection. The insoluble form (IF) was also suspended in saline prior to injection.

For later trials requiring larger quantities of immunogen of greater purity, the *E. coli* strains containing the TraTp-LHRH analogue gene fusion plasmids were grown in shake flasks at 30°C and induced at 41°C for 3h. Bacteria were harvested by centrifugation (17,000 g, for 20 min) and the cells lysed in 0.1M Tris-HCl pH 7.5, 50 mM EDTA using an APV Gaulin 15 MR homgenizer (7 passes at 9,000 psi). Following centrifugation (20 min, 10 000 x g), the insoluble pellet fraction containing the fusion protein was washed once with lysis buffer and the protein then solubilized in 10% SDS, 0.1M Tris-HCl pH 7.5, 25mM EDTA. This material was centrifuged (20 min x 15 000g) and the supernatant applied to a Sephacryl S-200 HR column equilibrated in 2% SDS, 50mM Tris-HCl pH 7.5, 25 mM EDTA. The column was eluted with this buffer and fractions containing the fusion protein (analysed by SDS-PAGE) are precipitated with 50% ethanol. The pellet was extracted twice with 1% Zwittergent 3-12, 0.1M Tris-HCl pH 7.5, 25 mM EDTA, and then resolubilized in 2% SDS. This material was applied to a hydroxyapatite column equilibrated with 50 mM Na phosphate buffer pH 6.5, 0.5% SDS, and eluted with a 0.05 - 0.5 M Na phosphate gradient pH 6.5 in 0.5% SDS. Fractions containing fusion protein were pooled and the purity analysed on SDS-PAGE. The protein concentration was determined by A<sub>280</sub> and amino acid analysis, and the lipopolysaccharide (LPS) content shown to be less than 1% (w/w). The final product was precipitated with 50% ethanol and resolubilized in 0.1% SDS prior to formulation.



EXAMPLE 3,METHODS FOR DETERMINING ANTIBODY AND TESTOSTERONE PRODUCTION  
IN SERUMA. ELISA

5 "Immulon 2" microelisa plates (Dynatech) were incubated overnight at 4°C with a 2µg/ml solution of ovalbumin-LHRH (prepared by EDAC conjugation) or 0.25µg/ml TraTp in 0.1M carbonate/bicarbonate pH 9.6 (100µl per well). After each step plates were washed 5 times with  
10 phosphate buffered saline containing 0.05% Tween (PBS/T). The plates were "blocked" with 200µl per well of 1% gelatine solution (Davis Gelatine Company Aust. Pty. Ltd.) in 0.1M carbonate/bicarbonate, for 1 hour at 37°C. The plates were washed as above. Sera were diluted 1:200 in  
15 PBS/T, and this was diluted two-fold in 100µl PBS/T. Sera were incubated for 1hr at 37°C.

After washing in PBS/T, conjugates coupled to peroxidase were added to plates at 1/2000 in PBS/T (100µl per well) and incubated at 37°C for 40 to 45 minutes. The  
20 conjugates were Goat anti-rat IgG, (KPL) Rabbit anti-mouse IgG, (KPL), Rabbit anti-dog IgG (Nordic), Goat anti-bovine IgG (KPL) and Rabbit anti-sheep IgG (Dako).

After washing, 100µl of peroxidase substrate was added to each well. This substrate consisted of 0.5mg/ml  
25 2, 2' - Azinobis (3-ethylbenzintiazoline sulfonic acid) (ABTS) in 0.1M citrate phosphate buffer pH 4.0, to which 0.1% H<sub>2</sub>O<sub>2</sub> was added immediately prior to addition to the plates. Unless otherwise stated, all chemicals and reagents used were of analytical grade from the Sigma Chemical  
30 Company.

B. LHRH TRACER BINDING ASSAY

Sera were diluted 1:500 in 0.01M phosphate buffered saline containing 0.5% w/v bovine serum albumin (PBS /BSA; referred to as buffer, below). One hundred microlitres of  
35 this dilution was added to 3 ml polypropylene radioimmunoassay tubes (Johns) containing 200µl of buffer. Added to this was 100µl of 10,000 cpm, (approx.)

- 24 -

of  $I^{125}$  LHRH (Amersham/Dupont) giving a 1:2000 final dilution of the antiserum.

The tubes were incubated overnight at room temperature (14 - 20°C). A second antibody (Sheep anti-mouse IgG or Sheep anti-dog IgG; Silenus); was diluted 1:20 with buffer, and added at 100µl per tube, then incubated 1 hr at room temperature.

Polyethylene glycol (1ml) 6000-7500 molecular weight (PEG, BDH) was added to each tube (except total counts), the tubes vortexed and then centrifuged for 30 minutes at 2,500 rpm. The supernatants were decanted and the tubes allowed to drain.

Pellets were counted in a multichannelled gamma counter (Clinigamma counter, LKB) for 1 minute. Results are expressed as a percentage (%) of total radioactive counts added [minus the non-specific binding (NSB)], to give a % of LHRH antibodies in the sera.

Unless otherwise stated, all chemicals and reagents used were of analytical grade from the Sigma Chemical Company.

#### C. MEASUREMENT OF TESTOSTERONE IN DOG SERUM

Testosterone was measured using a "Direct Testosterone commercial kit" (SPECTRIA, from Farnos Diagnostica, Finland), where the tubes supplied were pre-coated with second antibody. One hundred microliters of dog serum was added to the pre-coated tubes, in duplicate, followed by the addition of  $I^{125}$ -testosterone (200µl), testosterone antiserum (200µl; raised in rabbits) and incubated for exactly 2 h at 37°C. Castrate dog serum was added to the standard curve and QC's to compensate for any serum effects in the radioimmunoassay. Without centrifugation, the supernatants were decanted, tapped against absorbent paper, and washed with 1 ml of washing solution (phosphate buffer, supplied), allowed to drain, and subsequently counted in a multichannelled gamma counter (Clinigamma counter, LKB) for 1 minute. The data are presented as ng/ml of testosterone.

EXAMPLE 4.IMMUNISATION OF MICE WITH TraTp-LHRH ANALOGUE FUSION PROTEINS

In order to determine which TraTp-LHRH analogue fusion protein was most active in eliciting LHRH antibodies, groups of female Swiss mice (n = 5: 18-22g each) were immunised with 9 different TraTp-LHRH analogue fusion protein constructs in the absence of adjuvant (730p to 737p and 740p) and both the insoluble (IF) and soluble (SF) forms of the protein were compared. Control groups (N = 5) were immunised with TraTp prepared by the same methods.

Mice were injected with 150µg of protein in 100µl saline in each thigh muscle on Days 0 and 28.

Blood samples were collected from the retro-orbital plexus on Days 0, 28, and 42. Aliquots of sera from individual mice were pooled and analysed for LHRH antibody titre by ELISA and by an LHRH tracer binding assay. Data for bleeds on Day 42 are shown in Table 2.

The data show that only some of the fusion protein constructs, notably the proteins 732p, 733 and 740p were effective in raising LHRH antibodies when administered in saline. The sites for LHRH analogue insertion to generate an effective antigen could not have been predicted on inspection of the constructs made. Effective immunisation was achieved with both IF and SF materials from different constructs, assessed by determining the % binding to LHRH (& ELISA titres) and the concomitant effect on pregnancy (Table 2). The fusion proteins used in these experiments yield, single, well defined chemical entities which therefore have added advantages in stability, production, quality control and quality assurance compared to LHRH chemical conjugates.

EXAMPLE 5

T-CELL PROLIFERATIVE AND ANTIBODY RESPONSES IN DOGS  
IMMUNIZED WITH TraTp-LHRH ANALOGUE FUSION PROTEIN (732p) IN  
VARIOUS FORMULATIONS

This experiment was designed to determine whether the fusion protein 732p was capable of eliciting a T-cell, as well as an antibody response to LHRH in a target species such as the dog. A T-cell response may represent a

- 26 -

desirable effector mechanism in the immune castration process itself and/or it may provide T-cell help in the production of LHRH antibodies.

5 Immunization of dogs with Fusion proteins and the measurement of T-cell proliferation and antibody response.

Fifteen dogs of mixed ages, sexes and breeds were randomly divided into three groups of five animals. One group received 1 mg of pBTA 732 fusion protein in alhydrogel, another group was given 1 mg of fusion protein  
10 in Montanide ISA-20 while the third group was injected with 1 mg of the fusion protein construct in saponin. All three formulations contained 0.1% SDS. Animals were injected intramuscularly on Days 0, 28 and 56.

A. T-cell Proliferation

15 The T-cell response following immunisation with the fusion protein derived from pBTA 732 was measured as follows. Briefly, blood samples (5-10ml) were collected from the cephalic or jugular veins (before the Day 42) and a T-cell-enriched cell fraction was prepared as follows.  
20 About 10ml of heparinized blood was layered on 6ml of Ficoll-Paque (Pharmacia) and T-cells were separated by gradient centrifugation at 400 g for 30-40 min. The yield of T-cells recovered from 10ml of heparinized blood was between 15 to 20 x 10<sup>6</sup>. T-cells (10<sup>5</sup> in 0.2 ml of RPMI  
25 1640 medium (Flow Laboratories Inc., Mclean, Va, U.S.A.) containing 10% Fetal calf serum) were cultured in flat-bottom culture plates with varying amounts of TraTp, LHRH or PHA for 3 to 5 days at 37°C. Sixteen to eighteen hours before harvesting, cells were labelled with 0.5 µCi  
30 of tritiated thymidine, harvested and counted in a liquid Scintillation counter. Results are expressed as Stimulation indices, which are calculated by dividing the c.p.m. in the presence of antigen, by c.p.m. in the absence of antigen.

The data in Figure 6 show that strong T-cell  
35 responses were elicited against both TraTp and LHRH in all three groups. The protein, 732p formulated in saponin appeared to be more effective in evoking T-cell

responsiveness than in either Montanide ISA-20 or alhydrogel, particularly to LHRH. The strong T-cell responses obtained correlated reasonably well with the antibody responses to LHRH (as measured in a binding assay).

5     B.     Antibody response

1.     In order to determine the level of LHRH antibodies generated following immunisation with the fusion protein, 732p, blood samples (5-8ml) were collected from the cephalic or jugular veins on Days 0,28,42,56 & 70 and the sera (at  
10     dilution of 1:2000 final) analyzed for their ability to bind  $^{125}\text{I}$ -LHRH in an LHRH tracer binding assay (described in Example 3B).

       The data in Figure 7 show that antibodies to LHRH were elicited in dogs that had been immunized with the 732p  
15     fusion protein in an SDS/Saponin formulation, while the anti-LHRH response was much lower in animals that had received the fusion protein in alhydrogel or Montanide ISA-20. It appears, therefore, that saponin is a more effective adjuvant for this fusion protein, than either  
20     alhydrogel or Montanide ISA-20, for eliciting antibodies to LHRH.

2.     In order to assess the efficacy of a multi-LHRH analogue construct (862p) to stimulate LHRH antibodies, five dogs from the above experiment, four from the "Saponin  
25     group" and one from the Montanide ISA-20 group, were tested further as follows: on Day 121 (with respect to the primary immunisation) all five dogs received a further booster injection (booster #3 in Figure 8) of a TraTp-LHRH analogue fusion protein (862p) containing four inserts of LHRH  
30     analogue arranged in tandem; each dog received 500  $\mu\text{g}$  of this fusion protein construct in 0.05% saponin and 0.1% SDS. These dogs were bled on Days 121 (prior to booster #3), 134, 141, 148, 155, 162, 164 and 167. The data in Figure 8 show that high levels of LHRH antibodies were  
35     elicited in these five dogs in response to a TraTp fusion protein construct containing four inserts of LHRH analogue. The LHRH antibody response to 732p (booster 1 and booster 2 in Figure 8) are also shown by way of comparison.

- 28 -

These results indicated that the immunisation of dogs with a fusion protein containing multiple copies of LHRH analogue, in saponin and SDS, was capable of evoking a strong LHRH antibody response. This response resulted in complete diminution of testosterone synthesis with concomitant castration effects indicated by the reduction in testis and prostate weights; testes; 3.2 vs 9.6 grams in control dogs; and prostate: 1.5 vs 9.2 grams in control dogs with comparable body weights ranging from 12.0 to 17.0 kilograms (Figure 10). These data indicate that mixtures of fusion proteins for example 862p and 732p or derivatives of 732p may prove more efficacious than the administration of each alone.

Since the immunogenicity of the TraTp-LHRH analogue fusion proteins, formulated in saponin, was superior to that in alhydrogel or Montanide ISA-20, all subsequent work involving fusion protein constructs was performed using the saponin/SDS formulation.

#### EXAMPLE 6

#### 20 T-CELL PROLIFERATIVE RESPONSES IN DOGS IMMUNIZED WITH TraTp-LHRH ANALOGUE FUSION PROTEINS WITH MULTIPLE LHRH ANALOGUE INSERTS

In an attempt to enhance the immunogenicity of the LHRH analogue fusion proteins, we prepared constructs that would specify TraTp-LHRH analogue fusion proteins that contained one to eight LHRH analogue epitopes arranged in tandem. Following purification, the immunogenicity of the fusion proteins was tested in outbred mice and dogs.

The results in Figure 9 (a) indicate that in the dog, fusion proteins with multiple inserts of LHRH analogue generated a higher anti-LHRH response (as measured by the binding of  $^{125}\text{I}$ -LHRH; at a serum dilution of 1:2000 final) than constructs with a single insert. Indeed, there was an increase in LHRH binding which corresponded to an increase in the number of LHRH analogue inserts per molecule of TraTp. With regard to T-cell proliferation, there was an increase (in terms of stimulation index) in the responses to

LHRH, in vitro corresponding to the number of units of LHRH analogue in the carrier molecule (Figure 11). The T-cell data therefore confirm the trend seen for the antibody response to LHRH (Figure 11). TraTp-LHRH analogue fusions  
5 733p, 870p, 862p and 859p refer to fusion proteins, containing one, two, four and eight LHRH analogue inserts respectively, at the same site position in TraTp.

Outbred dogs (n=5 per group) were immunized intramuscularly on days 0 and 28 in two sites (0.5ml per  
10 site); while outbred mice (ARC Swiss; n=10 per group) were immunized intramuscularly in two sites, but, giving 1/10th of the dose (0.05 ml per site) administered to the dogs, with the fusion proteins as follows:

Group 1: 733 (750 µg in 0.075% saponin and 0.1% SDS); Group 2: 870p (790 µg in 0.079% saponin and 0.1% SDS); Group 3: 862p (860 µg in 0.086% saponin and 0.1% SDS) and Group 4: 859p (1 mg in 0.1% saponin and 0.1% SDS). Mice  
received a tenth of this dose. In dogs heparinised and non-heparinised blood samples (5-10ml) were collected from  
20 the jugular vein on Days 28 and 42 and T-cell proliferation, on Day 42, (was measured as described in a previous Section), and LHRH antibody response, on both Days 28 and 42; (as described in Example 4) were measured. In mice only the LHRH antibody response was measured in serum (0.4 ml of  
25 blood collected via the retro-orbital plexus route).

The results in Figure 9(a) show that on Day 42 in the dog, fusion proteins with multiple inserts of LHRH analogue were considerably more immunogenic (evoking a higher anti-LHRH response) than constructs with a single insert.  
30 In fact, there was a progressive increase in LHRH binding corresponding to the number of LHRH analogue inserts per molecule of TraTp. In contrast, in the mouse, peak binding was seen in the sera of animals given the 870p TraTp-LHRH analogue fusion protein, while the 862p and 859p proteins elicited a somewhat lower level of LHRH binding response  
35 (Figure 9b). On Day 28 (before the first booster) the levels of LHRH binding were low in both species although

- 30 -

there was a suggestion that in the mouse, the binding response decreased with an increase in the number of LHRH analogue inserts in the TraTp molecule. In the dog, on the other hand, a slight increase in LHRH antibody levels corresponded to an increase in the LHRH analogue units in the fusion protein construct. These observations indicate that the introduction of multiple repeats of a peptide into the TraTp molecule considerably enhances the immunogenicity (ability to evoke a higher anti-peptide response) of the inserted peptide. Furthermore, the most effective immunogen for any particular species could not have been established a priori. Nevertheless, the principles and procedures now established by the present invention provide means to apply the technology to other species and fusion proteins of commercial interest.

#### Industrial Applicability

The fusion proteins of the invention are of use in providing self-adjuvanting immunogens which can be administered to a vertebrate host in a carrier such as a saline solution or saponin to immunise that host against endogenous LHRH so as to inhibit the reproductive function of the host.

Notwithstanding the specific uses exemplified in this specification, the approach used here with regard to LHRH analogue fusions suggests a means for providing fusion proteins comprising TraTp with other immunogenic epitopes, those epitopes including peptides of natural or synthetic origin, including fragments of proteins. The proteins may be hormones or growth factors such as LHRH, LH, FSH, chorionic gonadotrophin (CG), adrenocorticotrophic hormone (ACTH), somatotrophin, somatostatin, insulin-like growth factors, inhibin, activin, follistatin and variants thereof; they may be proteins of biological interest such as sperm antigens or ovum antigens such as zona pellucida antigens; alternatively, they may be antigens derived from parasite proteins, such parasites including protozoans, nematodes, cestodes, insects and ticks; they may also include antigens



- 31 -

from bacteria or viruses, especially those protective against diseases in mammals, such diseases including cholera, AIDS, rabies, tetanus, smallpox, polio, diphtheria and others of commercial significance. It can be seen that in accordance with this invention fusion of TraTp and LHRH analogue sequences can be used to provide vaccines for immunising against LHRH and the present inventors believe that this approach could be extrapolated to the abovementioned further immunogenic epitopes on the basis of the teachings contained herein.

#### Deposition of Strains

E. coli strains have been deposited with the Australian Government Analytical Laboratories located at the Commonwealth Department of Administrative Services, New South Wales Regional Laboratory, 1 Suakin Street, Pymble, New South Wales 2073, Australia on 21 August 1990 in accordance with the Budapest Treaty under the following accession numbers:

<u>Strain No.</u>	<u>Accession No.</u>
BTA 1665	N90/031366
BTA 1666	N90/031367
BTA 1907	N90/031368

25

BTA 1349 carrying pBTA 439 was deposited with the American Type Culture Collection of 12301 Parklawn Drive, Rockville, MD 20852, U.S.A. under accession number ATCC 67331 on 2 March 1987, in accordance with the Budapest Treaty provisions.

35

-32-

**Table 1** TraTp-LHRH Fusion proteins

<u>TraTp-LHRH Fusion</u>	<u>Plasmid pBTA#</u>	<u>E. coli/ plasmid combination</u>	<u>Amino acid Insertion site in TraTp *</u>	<u>Number of LHRH Repeats</u>
609p	pBTA609	BTA1905	30/31	1
730p	pBTA730	BTA1663	241/242	1
731p	pBTA731	BTA1664	220/221	1
732p	pBTA732	BTA1665	80/81	1
733p	pBTA733	BTA1666	200/201	1
734p	pBTA734	BTA1667	175/176	1
735p	pBTA735	BTA1668	101/102	1
736p	pBTA736	BTA1669	80/81;220/221	1 at each site
737p	pBTA737	BTA1670	145/146	1
740p	pBTA740	BTA1907	235/236	1
859p	pBTA859	BTA2000	200/201	8
862p	pBTA862	BTA2004	200/201	4
870p	pBTA870	BTA2024	200/201	2

\* Amino acid 1 is the Met 1 of the TraTp signal sequence shown in Figure 2

Table 2. Antibodies raised in mice against TraTp-LHRH fusion proteins

Protein	TraTp TITRES*		LHRH TITRES*		Mean $^{125}$ I-LHRH binding (%)†		% Pregnant††	
	IF	SF	IF	SF	IF	SF	IF	SF
730p	2640	1520	100	100	7.4	0.0	83	100
731p	9280	12800	100	100	0.1	1.56	80	60
732p	1440	480	460	1920	0.0	64.3	40	0
733p	12800	12800	360	1040	26.5	22.4	50	20
734p	12800	12800	100	100	0.1	10.9	100	40
735p	5120	7680	100	100	1.5	2.7	75	60
736p	1920	500	100	720	0.4	17.4	50	25
737p	12800	12800	100	100	0.0	0.0	100	60
740p	2720	1360	360	380	52.9	65.4	50	0
TraTp	12800	12800	100	100	0.0	0.0	90	70

\*ELISA titres are the reciprocal of dilution to give O. D. = 0.5

†Results are expressed as a percentage (%) of total radioactive counts added (minus the non-specific bindings; NSB), to give a % of LHRH antibodies in the sera diluted 1 : 2000 final.

IF = Insoluble Form (n = 5/group); SF = Soluble Form (n = 5/group).

Data are from sera taken at Day 42.

††Males were introduced on Day 56 (after primary immunisation); mating was allowed over two cycles before withdrawing the males. Females were euthanased 10 days after this, and pregnancy status assessed.

- 34 -

## CLAIMS

1. A fusion protein comprising TraTp or an analogue thereof and an analogue of LHRH wherein at least one copy of the LHRH analogue is inserted in at least one site in the TraTp or TraTp analogue sequence or fused to the TraTp or TraTp analogue sequence and the fusion protein when administered to a vertebrate host is able to elicit production of antibodies against LHRH, which inhibit reproductive function of the vertebrate host.

2. A fusion protein according to claim 1, wherein the LHRH analogue is:

Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly.

15

3. A fusion protein according to claim 1 or claim 2, wherein at least one LHRH analogue is inserted between amino acids 80 and 81, 200 and 201 or 235 and 236 of the TraTp or TraTp analogue sequence or in a combination of these sites where amino acid 1 is the Met 1 of the TraTp signal sequence.

20

4. A fusion protein according to any one of claims 1 to 3, wherein the fusion protein is selected from 732p, 733p, 740p, 859p, 862p and 870p as herein defined.

25

5. A polynucleotide molecule encoding a fusion protein according to any one of claims 1 to 4.

6. A polynucleotide molecule according to claim 5, wherein the polynucleotide molecule is a recombinant DNA molecule comprising a plasmid vector.

30

7. A polynucleotide molecule according to claim 5 or claim 6, wherein expression of the fusion protein is under control of the  $P_L$  promoter.

35

- 35 -

8. A polynucleotide molecule according to claim 6 or claim 7, wherein the plasmid vector is pBTA 812.

9. A polynucleotide molecule according to any one of claims 5 to 8, wherein the polynucleotide molecule is a recombinant plasmid selected from:

pBTA 732, pBTA 733, pBTA 740, pBTA 859, pBTA 862 and pBTA 870, as herein defined.

10. A vaccine comprising an effective dose of at least one fusion protein according to any one of claims 1 to 4, together with a carrier, diluent, excipient and/or adjuvant suitable for human or veterinary use.

11. A vaccine according to claim 10 wherein the adjuvant is saponin.

12. A transformant host carrying a polynucleotide molecule according to any one of claims 5 to 9, wherein the polynucleotide molecule is in replicative form and the fusion protein can be expressed by the host.

13. A transformant host according to claim 12, wherein the host is an E. coli strain.

14. A transformant host according to claim 12 or 13, wherein the transformant host is selected from BTA 1665, BTA 1666, BTA 1907, BTA 2000, BTA 2004 and BTA 2024 as herein defined.

15. A method of controlling reproductive function in a vertebrate host comprising immunising the host with a fusion protein according to any one of claims 1 to 4, or a vaccine according to claim 10 or 11.

- 36 -

16. A method of inhibiting reproductive function in a vertebrate host comprising immunising the host with a fusion protein according to any one of claims 1 to 4, or a vaccine according to claim 10 or 11.

5

17. A method according to claim 15 or 16, wherein the host is a domestic animal.

10

15

20

25


30

35

1/12

Structure of pBTA812

Figure 1A



$P_L$  = Leftward promoter of Lambda

*TT* = Transcription terminator  
 Region 1302 - 3597 equals region 2066  
 (Pvu2 site)  
 to 4387. (EcoR1 site) of pBR322

*Amp<sup>r</sup>* = Ampicillin resistance gene

Diagram not to scale

2/12

Figure 1B

AGATCTCTCACCTACCAAACAATGCCCCCTGCAAAAAATAAATTCATATAAAAA

Operator-1 3                      Operator-1 2

ACATACAGATAACCATCTGCGGTGATAAATTATCTCTGGCGGTGTTGACATAAATACCAC

Operator-1 1                      mRNA----->                      TraT, 5' untranslated----->

TGGCGGTGATACTGAGCACATCAGCAGG/AATCCCAGCTCGATTATGGTTATAGTTCA

EcoRI

AAACGATATGATGAGTGAATCTTAATTTGTATATTATGAGCTTTTATTCAATATGAAGGAA

CATTGATG

TraT



3/12

## FIGURE 2

1  
 ATG AAA ATG AAA AAA TTG ATG ATG GTT GCA CTG GTC AGT TCC ACT CTG GCC CTT TCA GGG TGT GGT GCG ATG AGC ACA GCA ATC AAG AAG  
 Met Lys Met Lys Lys Leu Met Met Val Ala Leu Val Ser Ser Thr Leu Ala Leu Ser Glv Cys Gly Ala Met Ser Thr Ala Ile Lys Lys 30  
 signal sequence  
 91  
 CGT AAC CTT GAG GTG AAG ACT CAG ATG AGT GAG ACC ATC TGG CTT GAA CCC GCC AGC GAA CGC ACG GTA TTT CTG CAG ATC AAA AAC ACG  
 Arg Asn Leu Glu Val Lys Thr Gln Met Ser Glu Thr Ile Trp Leu Glu Pro Ala Ser Glu Arg Thr Val Phe Leu Gln Ile Lys Asn Thr 60  
 new PvuII  
 121  
 211  
 TCT GAT AAA GAC ATG AGT GGG CTG CAG GGC AAA ATT GCT GAT GCT GTG AAA GCA AAA GGA TAT CAG GTG GTG ACT TCT CCG GAT AAA GCC  
 Ser Asp Lys Asp Met Ser Gly Leu Gln Gly Lys Ile Ala Asp Ala Val Lys Ala Lys Gly Tyr Gln Val Val Thr Ser Pro Asp Lys Ala 90  
 EcoRV  
 301  
 271  
 TAC TAC TGG ATT CAG GCG AAT GTG CTG AAG GCG GAT AAG ATG GAT CTG CGG GAG TCT CAG GGA TGG CTG AAC CGT GGT TAT GAA GGC GCA  
 Tyr Trp Ile Gln Ala Asn Val Leu Lys Ala Asp Lys Met Asp Leu Arg Glu Ser Gln Gly Trp Leu Asn Arg Gly Tyr Glu Gly Ala 120  
 HaeIII  
 391  
 361  
 GCA GTT GGT GCA GCG TTA GGTGCC GGT ATT ACC GGT TAT AAC TCA AAT TCT GCC GGT GCC ACA CTC GGT GTA GGC CTT GCT GCT GGT CTG  
 Ala Val Gly Ala Ala Leu Gly Ala Gly Ile Thr Gly Tyr Asn Ser Asn Ser Ala Gly Ala Thr Leu Gly Val Gly Leu Ala Ala Gly Leu 150  
 481  
 511  
 451  
 GTG GGT ATG GCT GCA GAT GCG ATG GTG GAA GAT GTG AAC TAT ACC ATG ATC ACG GAT GTA CAG ATT GCA GAG CGT ACT AAG GCA ACG GTG  
 Val Gly Met Ala Ala Asp Ala Met Val Glu Asp Val Asn Tyr Thr Met Ile Thr Asp Val Gln Ile Ala Glu Arg Thr Lys Ala Thr Val 180  
 601  
 661  
 541  
 ACA ACG GAT AAT GTT GCC GCC CTG CGT CAG GGC ACA TCA GGT GCG AAA ATT CAG ACC AGT ACT GAA ACA GGT AAC CAG CAT AAA TAC CAG  
 Thr Thr Asp Asn Val Ala Ala Leu Arg Gln Gly Thr Ser Gly Ala Lys Ile Gln Thr Ser Thr Glu Thr Gly Asn Gln His Lys Tyr Gln 210  
 Scal  
 691  
 631  
 ACC CGT GTG GTT TCA AAT GCG AAC AAG GTT AAC CTG AAA TTT GAA GAG GCG AAG CCT GTT CTC GAA GAC CAA CTG GCC AAA TCA ATC GCA  
 Thr Arg Val Val Ser Asn Ala Asn Lys Val Asn Leu Lys Phe Glu Glu Ala Lys Pro Val Leu Glu Asp Gln Leu Ala Lys Ser Ile Ala 240  
 HpaI  
 721  
 AAT ATT CTC TGA  
 Asn Ile Leu ...  
 SspI 243

4/12

FIGURE 3.

TraT-LHRH FUSION PROTEINS

pBTA 609

TraT ———, LHRH ———, TraT ———  
 AAG.AAG.CAG.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.CTG.CTT.GAG.  
 Lys Lys Gln Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Leu Leu Glu  
 30 33

pBTA 732

TraT ———, LHRH ———, TraT ———  
 AAA.GGA.TCC.CCC.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.GAG.CAT.CAG.  
 Lys Gly Ser Pro Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Gln  
 80 82

pBTA 735

TraT ———, LHRH ———, TraT ———  
 AAG.GCC.CCC.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.GGG.AGC.TCC.GAT  
 Lys Ala Pro Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Gly Ser Ser Asp  
 101 102

pBTA 737

TraT ———, LHRH ———, TraT ———  
 GTA.GGA.GCT.CCC.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.GGG.GGC.CTT.GCT  
 Val Gly Ala Pro Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Gly Gly Leu Ala  
 145 146

pBTA 734

TraT ———, LHRH ———, TraT ———  
 GAG.CGT.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.ACT.AAG.  
 Glu Arg Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Thr Lys  
 175 176

pBTA 733

TraT ———, LHRH ———, TraT ———  
 ACC.AGT.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.ACT.GAA.  
 Thr Ser Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Thr Glu  
 200 201

pBTA 731

TraT ———, LHRH ———, TraT ———  
 AAG.GTT.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.AAC.CTG  
 Lys Val Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Asn Leu  
 220 221

pBTA 740

TraT ———, LHRH ———, TraT ———  
 CAA.CTG.GCC.CCC.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.GGG.AGC.TCC.AAA  
 Gln Leu Ala Pro Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Gly Ser Ser Lys  
 236 237

pBTA 730

TraT ———, LHRH ———, TraT ———  
 GCA.AAT.GAG.CAC.TGG.TCA.TAT.GGT.CTG.CGT.CCC.GGG.ATT.CTC.TGA  
 Ala Asn Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Ile Leu ...  
 241 242

5/12

FIGURE 1

a: Sequence of DNA fragments coding for LHRH.

GAG	CAC	TGG	TCA	TAT	GGT	CTG	CGT	<u>CCC</u>	<u>GGG</u>
GTC	GTG	ACC	AGT	ATA	CCA	GAC	GCA	<u>GGG</u>	<u>CCC</u>
Glu	His	Trp	Ser	Tyr	Gly	Leu	Arg	Pro	Gly

b) Sequence of linker DNA.

SmaI  
 CCCCCGGGAGCT  
 GGGGGCCCTCGA

c: Sequence of LHRH DNA used in the construction of pBTA 870.

GGT	GAA	CAT	TGG	AGC	TAC	GGT	CTA	<u>CCC</u>	<u>CCC</u>
CCA	CTT	GTA	ACC	TCG	ATG	CCA	GAT	<u>GGG</u>	<u>GGG</u>
Gly	Glu	His	Trp	Ser	Tyr	Gly	Leu	Arg	Pro

d) GGT.GAA.CAC.TGG.TCT.TAT.GGC.TTA.CGG.CCG.GGA.GAG.CAT.TGG.AGT.TAC.  
 CCA.CTT.GTG.ACC.AGA.ATA.CCG.AAT.GCC.GGC.CCT.CTC.GTA.ACC.TCA.ATG.  
 Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr

GGC.CTC.CGT.CCC  
 CCG.GAG.GCA.GGG  
 Gly Leu Arg Pro

6/12

**FIGURE 5**  
Sequence of multimers of LHRH in TraT

pBTA 870

TraT-----LHRH #1-----  
ACC..AGT..GAG..CAC..IGG..ICA..TAT..GGI..CTG..CGI..CCC..GGT.  
Thr Ser Glu His Trp Ser Tyr Gly Leu Arg Pro Gly  
200

LHRH #2-----TraT-----  
GAA..CAT..IGG..AGC..TAG..GGI..CTA..CGC..CCC..GGG ACT..GAA.  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Thr Glu  
201

pBTA 862

TraT-----LHRH #1-----LHRH #2-----  
ACC..AGT..GAG..CAC..IGG..ICA..TAT..GGI..CTG..CTG..CCC..GGT..GAA..CAT..IGG..AGC..TAC..GGT..CTA..CGC..CCC..GGT.  
Thr Ser Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly  
200

LHRH #3-----LHRH #4-----TraT-----  
GAA..CAC..IGG..ICT..TAT..GGC..TTC..CGG..CCG..GGA..GAG..CAT..IGG..AGT..TAC..GGC..CTC..CGT..CCC..GGG ACT..GAA  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Thr Glu  
201

pBTA 859

TraT-----LHRH #1-----LHRH #2-----  
ACC..AGT..GAG..CAC..IGG..ICA..TAT..GGI..CTG..CTG..CCC..GGT..GAA..CAT..IGG..AGC..TAC..GGT..CTA..CGC..CCC..GGT.  
Thr Ser Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly  
200


LHRH #3-----LHRH #4-----  
GAA..CAC..IGG..ICT..TAT..GGC..TTC..CGG..CCG..GGA..GAG..CAT..IGG..AGT..TAC..GGC..CTC..CGT..CCC..GGT  
Thr His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly

LHRH #5-----LHRH #6-----  
GAA..CAC..IGG..ICT..TAT..GGC..TTC..CGG..CCG..GGA..GAG..CAT..IGG..AGT..TAC..GGC..CTC..CGT..CCC..GGT  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly

LHRH #7-----LHRH #8-----TraT-----  
GAA..CAC..IGG..ICT..TAT..GGC..TTC..CGG..CCG..GGA..GAG..CAT..IGG..AGT..TAC..GGC..CTC..CGT..CCC..GGG ACT..GAA  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Thr Glu  
201


7/12

Figure 6




8/12

Figure 7



9/12

Figure 8



10/12





Figure 9



11/12

Figure 10

Dog 060/10



12/12




Figure 11

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) 6

According to International Patent Classification (IPC) or to both National Classification and IPC

Int. Cl.<sup>5</sup> C12N 15/62, 15/70, C12P 21/00, 21/02, C07K 7/20, 15/06, 15/12, A61K 39/385, 37/38 //  
(C12N 15/62, C12R:1/19) (C12N 15/70, C12R:1/19)

## II. FIELDS SEARCHED

Minimum Documentation Searched 7

Classification System |

Classification Symbols

IPC<sup>5</sup>

As above

Chem. Abs. Keywords: LHRH, Leuteinising, Leuteinizing AND antibod, antigen

WPAT Keywords: Fusion Protein AND Escherichia coli, E. coli

Documentation Searched other than Minimum Documentation  
to the extent that such Documents are Included in the Fields Searched 8AU : IPC<sup>5</sup> as above

## III. DOCUMENTS CONSIDERED TO BE RELEVANT 9

Category*	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages 12	Relevant to Claim No 13
Y	EP,A, 0055942 (THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK) 14 July 1982 (14.07.82) see claims	(1-17)
Y	AU,A, 73510/87 (BIOENTERPRISES PTY LTD) 5 November 1987 (05.11.87) see claims	(1-17)
Y	AU,A, 79453/87 (PROTEUS BIOTECHNOLOGY LTD) 8 December 1988 (08.12.88) see claims	(1-6,10,11,15-17)
Y	AU,A, 76423/87 (THE STATE OF VICTORIA) 14 January 1988 (14.01.88) see claims	(1-4,10,11,15-17)
Y	AU,B, 11017/88 (CSIRO) 10 August 1988 (10.08.88) see claims	(1-4,10,11,15-17)

\* Special categories of cited documents: 10

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"G"

document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the  
International Search  
1 November 1990 (01.11.90))Date of Mailing of this International  
Search Report

7 November 1990

International Searching Authority

Signature of Authorized Officer

Australian Patent Office

CEDRIC SCHAFFER

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers 15-17, because they relate to subject matter not required to be searched by this Authority, namely:  
Methods for treatment of the human or animal body by therapy, as well as by diagnostic methods.
2. ☐ Claim numbers , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim numbers 4-16, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4 (a):

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 2

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON  
INTERNATIONAL APPLICATION NO. PCT/AU 90/00373

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Members			
AU 79453/87	EP 293530	GB 2196969			
AU 76423/87	DK 1145/88 JP 1500900 WO 8800056	EP 274496 NO 880918 ZA 8704818	FI 880954 NZ 220932		
AU 73510/87	CN 87103784 JP 1500117	DK 6679/87 NZ 220027	EP 267204 WO 8706590		
EP 55942	DK 5823/81 US 4624926 IL 64783	GB 2091269 US 4666836	JP 57140800 CA 1207684		
AU 11017/88	WO 8805308	ZA 8800149			